ArticleJournal of immunology research2016
Yeast Surface-Displayed H5N1 Avian Influenza Vaccines.
Article in Journal of immunology research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 35 citations in OpenAlex.
- Oral yeast-displayed SARS-CoV-2 spike protein vaccine enhanced by trimerization and flagellin peptide.Scientific reports · 2026Article
- Cell surface display of VP1 of foot-and-mouth disease virus on Saccharomyces cerevisiae.Microbial cell factories · 2025Article
- Oral Immunization with Yeast-Surface Display of SARS-CoV-2 Antigens inInfectious disease reports · 2025Article
- Yeast vaccine production platform for human and animal infectious diseases.Frontiers in immunology · 2025Review
- Oral Yeast-Cell Microcapsule-Mediated DNA Vaccines AgainstVaccines · 2024Article
- Recent Advances in Oral Vaccines for Animals.Veterinary sciences · 2024Review
- Quantitative measurement of cell-surface displayed proteins based on split-GFP assembly.Microbial cell factories · 2024Article
- Whole Yeast Vaccine Displaying ZIKV B and T Cell Epitopes Induces Cellular Immune Responses in the Murine Model.Pharmaceutics · 2023Article
- Hemagglutinin expressed by yeast reshapes immune microenvironment and gut microbiota to trigger diverse anti-infection response in infected birds.Frontiers in immunology · 2023Article
- Improving the functionality of surface-engineered yeast cells by altering the cell wall morphology of the host strain.Applied microbiology and biotechnology · 2021Article
- High immune efficacy against different avian influenza H5N1 viruses due to oral administration of a Saccharomyces cerevisiae-based vaccine in chickens.Scientific reports · 2021Article
- Yeast Surface Display System: Strategies for Improvement and Biotechnological Applications.Frontiers in bioengineering and biotechnology · 2021Review
- Yeast display platform technology to prepare oral vaccine against lethal H7N9 virus challenge in mice.Microbial cell factories · 2020Article
- Alternative Experimental Models for Studying Influenza Proteins, Host-Virus Interactions and Anti-Influenza Drugs.Pharmaceuticals (Basel, Switzerland) · 2019Review
- Review
- A Highly Efficient IndirectMolecules (Basel, Switzerland) · 2019Article
- Evaluation of cell-surface displayed synthetic consensus dengue EDIII cells as a potent oral vaccine candidate.Microbial cell factories · 2018Article
- Antibody Engineering for Pursuing a Healthier Future.Frontiers in microbiology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Highly pathogenic H5N1 avian influenza viruses pose a pandemic threat to human health. A rapid vaccine production against fast outbreak is desired. We report, herein, a paradigm-shift influenza vaccine technology by presenting H5N1 hemagglutinin (HA) to the surface of yeast. We demonstrated, for the first time, that the HA surface-presented yeast can be used as influenza vaccines to elicit both humoral and cell-mediated immunity in mice. The HI titer of antisera reached up to 128 in vaccinated mice. A high level of H5N1 HA-specific IgG1 and IgG2a antibody production was detected after boost immunization. Furthermore, we demonstrated that the yeast surface-displayed HA preserves its antigenic sites. It preferentially binds to both avian- and human-type receptors. In addition, the vaccine exhibited high cross-reactivity to both homologous and heterologous H5N1 viruses. A high level production of anti-HA antibodies was detected in the mice five months after vaccination. Finally, our animal experimental results indicated that the yeast vaccine offered complete protection of mice from lethal H5N1 virus challenge. No severe side effect of yeast vaccines was noted in animal studies. This new technology allows for rapid and large-scale production of influenza vaccines for prepandemic preparation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.